CAPTRUST Financial Advisors
TGTX icon

CAPTRUST Financial Advisors’s TG Therapeutics TGTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$605K Buy
11,003
+3,735
+51% +$153K ﹤0.01% 2044
2026
Q1 		$241K Buy
7,268
+493
+7% +$14.7K ﹤0.01% 2551
2025
Q4 		$202K Buy
+6,775
New +$221K ﹤0.01% 2519
2025
Q3 		– Sell
-5,734
Closed -$206K – 2716
2025
Q2 		$206K Sell
5,734
-838
-13% -$31.2K ﹤0.01% 2289
2025
Q1 		$259K Sell
6,572
-990
-13% -$33.3K ﹤0.01% 2020
2024
Q4 		$228K Sell
7,562
-22,765
-75% -$653K ﹤0.01% 2080
2024
Q3 		$709K Buy
30,327
+5,279
+21% +$115K ﹤0.01% 1404
2024
Q2 		$446K Buy
25,048
+351
+1% +$5.6K ﹤0.01% 1568
2024
Q1 		$376K Sell
24,697
-5,651
-19% -$90K ﹤0.01% 1647
2023
Q4 		$518K Buy
30,348
+5,588
+23% +$64.9K ﹤0.01% 1713
2023
Q3 		$207K Sell
24,760
-1,782
-7% -$24.8K ﹤0.01% 2269
2023
Q2 		$659K Buy
26,542
+629
+2% +$16.2K ﹤0.01% 1473
2023
Q1 		$390K Buy
25,913
+2,854
+12% +$43.4K ﹤0.01% 1550
2022
Q4 		$273K Buy
23,059
+194
+0.8% +$1.41K ﹤0.01% 1734
2022
Q3 		$135K Buy
22,865
+22,600
+8,528% +$148K ﹤0.01% 1895
2022
Q2 		$1K Sell
265
-147
-36% -$918 ﹤0.01% 4751
2022
Q1 		$4K Buy
412
+312
+312% +$3.61K ﹤0.01% 4278
2021
Q4 		$2K Sell
100
-11
-10% -$286 ﹤0.01% 4451
2021
Q3 		$4K Sell
111
-8
-7% -$248 ﹤0.01% 4054
2021
Q2 		$5K Sell
119
-6
-5% -$236 ﹤0.01% 3879
2021
Q1 		$6K Sell
125
-760
-86% -$36.5K ﹤0.01% 3674
2020
Q4 		$46K Sell
885
-50
-5% -$1.69K ﹤0.01% 1874
2020
Q3 		$25K Buy
935
+200
+27% +$4.6K ﹤0.01% 1884
2020
Q2 		$15K Buy
+735
New +$11.8K ﹤0.01% 2057
2019
Q4 		– Sell
-600
Closed -$3K – 1731
2019
Q3 		$3K Hold
600
– – ﹤0.01% 1754
2019
Q2 		$5K Hold
600
– – ﹤0.01% 1656
2019
Q1 		$5K Buy
+600
New +$3.24K ﹤0.01% 1541

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

CAPTRUST Financial Advisors's TGTX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its TG Therapeutics (TGTX) stake by 51% in Q2 2026, buying an estimated $153K and bringing the position to 11,003 shares worth $605K. The position accounts for ﹤0.01% of the portfolio, ranked #2044.

CAPTRUST Financial Advisors first reported a position in TGTX in Q1 2019 and has held it in 27 quarters since. The position peaked at $709K in Q3 2024. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • CAPTRUST Financial Advisors held 11,003 shares of TG Therapeutics worth $605K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 3,735 TG Therapeutics shares in Q2 2026, an estimated $153K.
  • TG Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2044 holding.
  • CAPTRUST Financial Advisors first reported a position in TG Therapeutics in Q1 2019 and has held it in 27 quarters since.
  • CAPTRUST Financial Advisors's TG Therapeutics position peaked at $709K in Q3 2024.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.